AR041508A1 - Compuestos con actividad en los receptores de glutamato metabotropicos - Google Patents
Compuestos con actividad en los receptores de glutamato metabotropicosInfo
- Publication number
- AR041508A1 AR041508A1 ARP030102892A ARP030102892A AR041508A1 AR 041508 A1 AR041508 A1 AR 041508A1 AR P030102892 A ARP030102892 A AR P030102892A AR P030102892 A ARP030102892 A AR P030102892A AR 041508 A1 AR041508 A1 AR 041508A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- nr6r7
- 4alkyl
- 3alkyl
- 6alkylnr6
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos exhiben actividad en los receptores de glutamato metabotrópicos en especial a nivel del receptor m GluR5 por lo tanto son útiles para trastornos neurológicos, psiquiátricos agudos y dolor. También se reivindican formulaciones farmacéuticas, procesos para preparar los compuestos, usos y métodos. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1) donde: P se selecciona entre el grupo formado por C3-7 alquilo y un anillo de entre 3 y 8 miembros que contiene uno o más átomos seleccionados en forma independiente entre C, N, O o S, donde dicho anillo puede fusionarse con un anillo de 5 o 6 miembros que contiene uno o más átomos seleccionados en forma independiente entre C, N, O o S; R1 se selecciona entre el grupo formado por H, hidroxi, halo, nitro, C1-6alquilhalo, OC1-6alquilhalo, C1-6alquilo, OC1-6alquilo, C2-6alquenilo, OC2-6alquenilo, C2-6alquinilo, OC2-6alquinilo, C0-6alquilC3-6cicloalquilo, OC0-6alquilC3-6cicloalquilo, C0-6alquilarilo, OC0-6alquilarilo, (CO)R6, O(CO)R6, O(CO)OR6, C1-6alquilOR6, OC2-6alquilOR6, C1-6alquil(CO)R6, OC1-6alquil(CO)R6, C0-6alquilCO2R6, OC1-6alquilCO2R6, C0-6alquilciano, OC2-6alquilciano, C0-6alquilNR6R7, OC2-6alquilNR6R7, C1-6alquil(CO)NR6R7, OC1-6alquil(CO)NR6R7, C0-6alquilNR6(CO)R7, OC2-6alquilNR6(CO)R7, C0-6alquilNR6(CO)NR6R7, C0-6alquilSR6, OC2-6alquilSR6, C0-6alquil(SO)R6, OC2-6alquil(SO)R6, C0-6alquilSO2R6, OC2-6alquilSO2R6, C0-6alquil(SO2)NR6R7, OC2-6alquil(SO2)NR6R7, C0-6alquilNR6(SO2)R7, OC2-6alquilNR6(SO2)R7, C0-6alquilNR6(SO2)NR6R7, OC2-6alquilNR6(SO2)NR6R7, (CO)NR6R7, O(CO)NR6R7, NR6OR7, C0-6alquilNR6(CO)OR7, OC2-6alquilNR6(CO)OR7, SO3R6 y un anillo de 5 o 6 miembros que contiene uno o más átomos seleccionados en forma independiente entre C, N, O o S, donde dicho anillo puede estar sustituido por uno o más A; M1 se selecciona entre el grupo formado por un enlace, C1-3alquilo, C2-3alquenilo, C2-3alquinilo, C0-4alquil(CO)C0-4alquilo, C0-3alquilOC0-3alquilo, C0-3alquil(CO)NR7R6, C0-3alquil(CO)NR7R6C1-3alquilo, C0-4alquilNR7R6, C0-3alquilSC0-3alquilo, C0-3alquil(SO)C0-3alquilo y C0-3alquil(SO2)C0-3alquilo; X1, X2 y X3 se seleccionan en forma independiente entre el grupo formado por CR, CO, N, NR, O y S; R se selecciona entre el grupo formado por H, C0-3alquuilo, halo, C0-3alquilOR5, C0-3alquilNR5R6, C0-3alquil(CO)OR5, C0-3alquilNR5R6 y C0-3alquilarilo; R2 se selecciona entre el grupo formado por H, hidroxi, oxo, =NR6, =NOR6, C1-4alquilhalo, halo, C1-4alquilo, OC1-4alquilo, O(CO)C1-4alquilo, C1-4alquil(SO)C0-4alquilo, C1-4alquil(SO2)C0-4alquilo, (SO)C0-4alquilo, (SO2)C0-4alquilo, OC1-4alquilo, C0-4alquilciano, C1-4alquilOR6 y C0-4alquilNR6R7; M2 se selecciona entre el grupo formado por un enlace, C1-3alquilo, C2-3 alquenilo, C2-3alquinilo, C0-4alquil(CO)C0-4alquilo, C0-3alquilOC0-3alquilo, C0-3alquilNR6C1-3alquilo, C0-3alquil(CO)NR6, C0-4alquilNR6R7, C0-3alquilSC0-3alquilo, C0-3alquil(SO)C0-3alquilo y C0-3alquil(SO2)C0-3alquilo; R3 se selecciona entre el grupo formado por H, hidroxi, oxo, =NR6, =NOR6, C1-4alquilhalo, halo, C1-4alquilo, OC1-4alquilo, O(CO)C1-4alquilo, C1-4alquil(SO)C0-4alquilo, C1-4alquil(SO2)C0-4alquilo, (SO)C0-4alquilo, (SO2)C0-4alquilo, C0-4alquilciano, C1-4alquilOR6 y C0-4alquilNR6R7; X4 se selecciona entre C, CR o N; X5 se selecciona entre C, CR, o N; Q es un anillo de 4 a 8 miembros o biciclo que contiene uno o más átomos seleccionados en forma independiente entre C, N, O o S, donde dicho anillo o biciclo puede fusionarse con un anillo de 5 o 6 miembros que contiene uno o más átomos seleccionados en forma independiente entre C, N, O o S y donde el anillo fusionado puede sustituirse con uno o más A; R4 se selecciona entre el grupo formado por H, hidroxi, halo, nitro, oxo, C1-6alquilhalo, C1-6alquilo, OC1-6alquilo, C0-6alquilC3-6cicloalquilo, C0-6alquilarilo, OC0-6alquilarilo, (CO)R6, O(CO)R6, C1-6alquilOR6, OC2-6alquilOR6, C1-6alquil(CO)R6, OC1-6alquil(CO)R6, C0-6alquilCO2R6, OC1-6alquilCO2R6, C0-6alquilciano, OC1-6alquilciano, C0-6alquilNR6R7, OC2-6alquilNR6R7, C0-6alquil(CO)NR6R7, OC0-6alquil(CO)NR6R7, C0-6alquilNR6(CO)R7, OC2-6alquilNR6(CO)R7, C0-6alquilNR6(CO)NR6R7, C0-6alquilSR6, OC2-6alquilSR6, C0-6alquil(SO)R6, OC2-6alquil(SO)R6, C0-6alquilSO2R6, OC0-6alquilSO2R6, C0-6alquil(SO2)NR6R7, OC0-6alquil(SO2)NR6R7, C0-6alquilNR6(SO2)R7, OC2-6alquilNR6(SO2)R7, NR6OR7, NR6(CO)OR7, SO3R6 y un anillo de 5 o 6 miembros que contiene uno o más átomos seleccionados en forma independiente entre C, N, O o S, donde dicho anillo puede estar sustituido por uno o más A; R5 se selecciona entre el grupo formado por H, hidroxi, halo, oxo, C1-6alquilhalo, OC1-6alquilhalo, C1-6alquilo, OC1-6alquilo, C0-6alquilC3-6cicloalquilo, C0-6alquilarilo, OC0-6alquilarilo, (CO)R6, O(CO)R6, O(CO)OR6, (CO)OR6, C1-6alquilOR6, OC2-6alquilOR6, C1-6alquil(CO)R6, OC1-6alquil(CO)R6, C0-6alquilCO2R6, OC1-6alquilCO2R6, C0-6alquilciano, OC0-6alquilciano, C0-6alquilNR6R7, OC2-6alquilNR6R7, C1-6alquil(CO)NR6R7, C0-6alquil(CO)heteroarilo, C0-6alquil(CO)arilo, OC1-6alquil(CO)NR6R7, C1-6alquil(CO)NR6R7, C0-6alquilNR6(CO)R7, OC2-6alquilNR6(CO)R7, C0-6alquilNR6(CO)NR6R7, C1-6alquilNR6(CO)OR7, C0-6alquilSR6, OC2-6alquilSR6, C0-6alquil(SO)R6, OC1-6alquil(SO)R6, C0-6alquilSO2R6, OC0-6alquilSO2R6, C0-6alquil(SO2)NR6R7, OC0-6alquil(SO2)NR6R7, C0-6alquilNR6(SO2)R7, OC2-6alquilNR6(SO2)R7, C0-6alquilNR6(SO2)NR6R7, OC2-6alquilNR6(SO2)NR6R7, (CO)NR6R7, O(CO)NR6R7, NR6OR7, NR6(CO)OR7, SO3R6 y un anillo de 5 o 6 miembros que contiene uno o más átomos seleccionados en forma independiente entre C, N, O o S, donde dicho anillo puede estar sustituido por uno o más A; R6 y R7 se seleccionan en forma independiente entre H, C1-6alquilo, C0-6alquilC3-6cicloalquilo, C0-6alquilarilo, C1-6alquilheteroarilo y un anillo de 5 o 6 miembros que contiene uno o más átomos seleccionados en forma independiente entre C, N O, o S, y donde R6 Y R7 pueden formar juntos un anillo de 5 o 6 miembros que contiene uno o más átomos seleccionados en forma independiente entre C, N O o S; donde cualquier C1-6alquilo, C2-6alquenilo, C2-6alquinilo, C0-6alquilC3-6cicloalquilo, C0-6alquilarilo y C0-6alquilheteroarilo definido bajo R1, R2, R3, R4, R5, R6 y R7 puede sustituirse con uno o más A; A se selecciona entre el grupo formado por H, hidroxi, oxo, halo, nitro, C1-6alquilhalo, OC1-6alquilhalo, C1-6alquilo, C0-4alquilC3-6cicloalquilo, C2-6alquenilo, OC1-6alquilo, C0-3alquilarilo, C1-6alquilOR6, OC2-6alquilOR6, C1-6alquilSR6, OC2-6alquilSR6, (CO)R6, O(CO)R6, OC2-6alquilciano, C0-6alquilciano, C0-6alquilCO2R6, OC1-6alquilCO2R6, O(CO)OR6, OC1-6alquil(CO)R6, C1-6alquil(CO)R6, NR6OR7, C0-6alquiNR6R7, OC2-6alquilNR6R7, C0-6alquil(CO)NR6R7, OC1-6alquil(CO)NR6R7, OC2-6alquilNR6(CO)R7, C0-6alquilNR6(CO)R7, C0-6alquilNR6(CO)NR6R7, O(CO)NR6R7, NR6(CO)OR7, C0-6alquil(SO2)NR6R7, OC2-6alquil(SO2)NR6R7, C0-6alquilNR6(SO2)R7, OC2-6alquilNR6(SO2)R7, SO3R6, C1-6alquilNR6(SO2)NR6R7, OC2-6alquil(SO2)R6, C0-6alquil(SO2)R6, C0-6alquil(SO)R6 y OC2-6alquil(SO)R6; m y p se seleccionan en forma independiente entre el grupo formado por 0, 1, 2, 3 y 4; n o y q se seleccionan cada uno en forma independiente entre 0, 1, 2, o 3; o su sal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40203902P | 2002-08-09 | 2002-08-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR041508A1 true AR041508A1 (es) | 2005-05-18 |
Family
ID=31715776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030102892A AR041508A1 (es) | 2002-08-09 | 2003-08-08 | Compuestos con actividad en los receptores de glutamato metabotropicos |
Country Status (16)
Country | Link |
---|---|
US (2) | US20040132726A1 (es) |
EP (1) | EP1536790A2 (es) |
JP (1) | JP2006506340A (es) |
KR (1) | KR20050039846A (es) |
CN (1) | CN1691944A (es) |
AR (1) | AR041508A1 (es) |
AU (1) | AU2003268064A1 (es) |
BR (1) | BR0313266A (es) |
CA (1) | CA2495120A1 (es) |
IL (1) | IL166650A0 (es) |
MX (1) | MXPA05001592A (es) |
NO (1) | NO20051223L (es) |
NZ (1) | NZ538339A (es) |
TW (2) | TW200424183A (es) |
WO (1) | WO2004014370A2 (es) |
ZA (1) | ZA200501101B (es) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1618098E (pt) | 2003-04-11 | 2015-02-10 | Ptc Therapeutics Inc | Compostos de ácido 1,2,4-oxadiazolebenzóico e sua utilização para supressão sem sentido e o tratamento de doenças |
US7932272B2 (en) | 2003-09-30 | 2011-04-26 | Eisai R&D Management Co., Ltd. | Antifungal agent containing heterocyclic compound |
WO2005077373A2 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
AU2005214380A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders |
BRPI0507499A (pt) * | 2004-02-18 | 2007-07-24 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5 |
US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
EP1740559B1 (en) * | 2004-04-20 | 2014-10-15 | Merck Sharp & Dohme Corp. | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
EP1764362A4 (en) * | 2004-06-30 | 2009-12-30 | Banyu Pharma Co Ltd | DERIVATIVES OF BIARYLES |
JP4557685B2 (ja) | 2004-11-15 | 2010-10-06 | 独立行政法人理化学研究所 | 蛍光蛋白質 |
WO2006089076A2 (en) | 2005-02-18 | 2006-08-24 | Neurogen Corporation | Thiazole amides, imidazole amides and related analogues |
US8101618B2 (en) * | 2005-04-06 | 2012-01-24 | Msd K.K. | 1,4-substituted piperazine derivatives |
ES2390804T3 (es) | 2005-04-08 | 2012-11-16 | Ptc Therapeutics, Inc. | Composiciones de un 1,2,4-oxadiazol oralmente activo para terapia de supresión de la mutación sin sentido |
JP3789465B1 (ja) | 2005-04-28 | 2006-06-21 | 学校法人立教学院 | イソオキサゾール誘導体又はジヒドロイソオキサゾール誘導体の製造方法 |
WO2006123255A2 (en) * | 2005-05-18 | 2006-11-23 | Addex Pharma Sa | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
GB0510140D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
TW200800946A (en) * | 2005-08-15 | 2008-01-01 | Astrazeneca Ab | Substituted piperazines as metabotropic glutamate receptor antagonists |
TW200800204A (en) * | 2005-08-15 | 2008-01-01 | Astrazeneca Ab | Bicyclic piperazines as metabotropic glutatmate receptor antagonists |
UY29796A1 (es) | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
EP2387995A1 (en) | 2006-03-30 | 2011-11-23 | PTC Therapeutics, Inc. | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith |
TW200811179A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators VI |
TW200808800A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGluR5 modulators V |
TW200811157A (en) | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
CA2657247A1 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
BRPI0716996B8 (pt) * | 2006-09-08 | 2021-05-25 | Ptc Therapeutics Inc | processo para preparar um composto |
EP2065377B1 (en) | 2006-09-21 | 2011-11-23 | Eisai R&D Management Co., Ltd. | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same |
WO2008130370A1 (en) | 2006-09-25 | 2008-10-30 | Ptc Therapeutics, Inc. | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression |
ES2563958T3 (es) | 2006-09-25 | 2016-03-16 | Ptc Therapeutics, Inc. | Formas cristalinas del ácido 3-[5-(2-fluorofenil)-[1,2,4]-oxadiazol-3-il]-benzoico |
KR20090074231A (ko) * | 2006-10-12 | 2009-07-06 | 피티씨 테라퓨틱스, 인크. | 넌센스 돌연변이 억제 치료를 위한 경구 활성 1,2,4-옥사디아졸의 투여 방법 |
WO2008050200A1 (en) * | 2006-10-24 | 2008-05-02 | Pfizer Products Inc. | Oxadiazole compounds as calcium channel antagonists |
UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
WO2008117148A1 (en) * | 2007-03-23 | 2008-10-02 | Pfizer Products Inc. | Substituted oxadiazole analogs as calcium channel antagonists |
TW200841879A (en) | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
KR101608702B1 (ko) | 2007-06-05 | 2016-04-04 | 사노피 | 디(헤테로)아릴사이클로헥산 유도체, 이들의 제조방법, 이들의 용도 및 이들을 포함하는 약제학적 조성물 |
MY180558A (en) * | 2007-09-21 | 2020-12-02 | Array Biopharma Inc | Pyridin-2-yl-amino-1,2,4- theiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
CA2704684A1 (en) | 2007-11-07 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
JP5502077B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規な化合物 |
EP2280705B1 (en) | 2008-06-05 | 2014-10-08 | Glaxo Group Limited | Novel compounds |
EP2300437B1 (en) | 2008-06-05 | 2013-11-20 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
CA2730037A1 (en) | 2008-07-10 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
PE20110397A1 (es) | 2008-09-25 | 2011-07-01 | Boehringer Ingelheim Int | Compuestos que modulan selectivamente el receptor cb2 |
US8188119B2 (en) | 2008-10-24 | 2012-05-29 | Eisai R&D Management Co., Ltd | Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same |
DE102009041241A1 (de) | 2009-09-11 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Substituierte Aryl-Verbindungen und ihre Verwendung |
DE102008057364A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Aryl-Verbindungen und ihre Verwendung |
DE102009041242A1 (de) | 2009-09-11 | 2011-12-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
DE102008057344A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung |
DE102008057343A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
MY157017A (en) | 2009-01-12 | 2016-04-15 | Pfizer Ltd | Sulfonamide derivatives |
US8609711B2 (en) * | 2009-01-30 | 2013-12-17 | Glaxosmithkline Llc | Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride |
JP5705748B2 (ja) | 2009-02-18 | 2015-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を変調する複素環化合物 |
US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
TWI562992B (en) | 2009-04-30 | 2016-12-21 | Glaxo Group Ltd | Indazole derivative, pharmaceutical composition thereof, and use thereof as inhibitors of kinase activity |
EP2438059A1 (en) | 2009-06-05 | 2012-04-11 | Link Medicine Corporation | Aminopyrrolidinone derivatives and uses thereof |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
WO2010147791A1 (en) | 2009-06-16 | 2010-12-23 | Boehringer Ingelheim International Gmbh | Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor |
JP2013505295A (ja) | 2009-09-22 | 2013-02-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を選択的に調節する化合物 |
JP2013517271A (ja) | 2010-01-15 | 2013-05-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
JP5746228B2 (ja) | 2010-03-05 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を選択的に調節するテトラゾール化合物 |
WO2011126903A2 (en) | 2010-03-30 | 2011-10-13 | Verseon, Inc. | Multisubstituted aromatic compounds as inhibitors of thrombin |
US9145407B2 (en) | 2010-07-09 | 2015-09-29 | Pfizer Limited | Sulfonamide compounds |
US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
AR086113A1 (es) | 2011-04-30 | 2013-11-20 | Abbott Lab | Isoxazolinas como agentes terapeuticos |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
JP2013028559A (ja) * | 2011-07-28 | 2013-02-07 | Nippon Light Metal Co Ltd | 3−クロロ−4−メチル安息香酸イソプロピル及びその製造方法 |
MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
US9040712B2 (en) | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
KR102194745B1 (ko) | 2013-03-13 | 2020-12-24 | 포르마 세라퓨틱스 인크. | Fasn 억제용 신규 화합물 및 조성물 |
AU2014238478B2 (en) | 2013-03-15 | 2018-07-19 | Verseon Corporation | Halogenopyrazoles as inhibitors of thrombin |
US20160083343A1 (en) | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc | Compounds and uses thereof for the modulation of hemoglobin |
CN110179795A (zh) | 2013-03-15 | 2019-08-30 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途 |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US9663529B2 (en) | 2013-07-02 | 2017-05-30 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
EP3016951B1 (en) | 2013-07-02 | 2017-05-31 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
MX2020011652A (es) | 2013-07-31 | 2022-09-27 | Novartis Ag | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. |
EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
EP2907806A1 (en) * | 2014-02-14 | 2015-08-19 | Universita Degli Studi Di Genova | New compounds as selective PDE4D inhibitors |
CN106455571A (zh) | 2014-03-06 | 2017-02-22 | Ptc医疗公司 | 1,2,4‑噁二唑苯甲酸的药物组合物和盐 |
BR112017000042B1 (pt) | 2014-07-03 | 2021-11-03 | Celgene Quanticel Research, Inc | Composto inibidores de desmetilase-1 lisina-específica e uso do mesmo, composição farmacêutica e método in vitro para regular a transcrição gênica em uma célula |
US10189810B2 (en) * | 2014-09-17 | 2019-01-29 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
MX2017010899A (es) | 2015-02-24 | 2017-11-24 | Bayer Cropscience Ag | Proceso para la preparacion de triazoles. |
HRP20221287T1 (hr) | 2015-02-27 | 2023-02-03 | Verseon International Corporation | Supstituirani pirazolni spojevi kao inhibitori serin proteaze |
EP3353182A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
WO2017075312A1 (en) | 2015-10-30 | 2017-05-04 | Ptc Therapeutics, Inc. | Methods for treating epilepsy |
WO2017218337A1 (en) | 2016-06-13 | 2017-12-21 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
US11008325B2 (en) | 2016-11-14 | 2021-05-18 | Virginia Commonwealth University | Inhibitors of cancer invasion, attachment, and/or metastasis |
ES2927019T3 (es) | 2017-03-28 | 2022-11-02 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas |
CN107382990B (zh) * | 2017-08-09 | 2020-08-04 | 济南大学 | 一种具有1,2,4-恶二唑结构片段的化合物及其制备方法和应用 |
EA202090871A1 (ru) | 2017-10-06 | 2020-07-03 | Форма Терапьютикс, Инк. | Ингибирование убиквитин-специфической пептидазы 30 |
ES2945834T3 (es) | 2018-10-05 | 2023-07-07 | Forma Therapeutics Inc | Pirrolinas fusionadas que actúan como inhibidores de la proteasa 30 específica de ubiquitina (USP30) |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
WO2020092395A1 (en) | 2018-10-29 | 2020-05-07 | Forma Therapeutics, Inc. | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE |
SG11202107434PA (en) | 2019-01-15 | 2021-08-30 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
EP3917913A2 (en) | 2019-01-31 | 2021-12-08 | Pfizer Inc. | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 |
EP3927683A1 (en) | 2019-02-19 | 2021-12-29 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
CN113248455A (zh) * | 2021-05-25 | 2021-08-13 | 湖北科技学院 | 一种3,5-二取代异噁唑类衍生物及其合成方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3740434A (en) * | 1966-12-23 | 1973-06-19 | American Cyanamid Co | Substituted nitroimidazolylthiadiazoles and oxadiazoles as antiprotozoal agents |
US3816426A (en) * | 1970-10-27 | 1974-06-11 | Abbott Lab | 1-(5-phenyl-4-oxo-2-oxazolin-2-yl)piperazines |
JPS56127364A (en) * | 1980-03-01 | 1981-10-06 | Mitsui Toatsu Chem Inc | Novel piperazine compound, its preparation and utilization |
JP3003148B2 (ja) * | 1989-01-05 | 2000-01-24 | 藤沢薬品工業株式会社 | チアゾール化合物、その製造法およびそれを含有する医薬組成物 |
IL96891A0 (en) * | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
US5631269A (en) * | 1992-10-23 | 1997-05-20 | Merck Sharp & Dohme Limited | Dopamine receptor subtype ligands |
DE19858191A1 (de) * | 1998-12-17 | 2000-06-21 | Aventis Cropscience Gmbh | 4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclyl-pyrimidine und ihre Verwendung als Repellentien |
CO5170501A1 (es) * | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
AU780191B2 (en) * | 1999-08-19 | 2005-03-03 | Astrazeneca Ab | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
TWI292316B (en) * | 1999-10-11 | 2008-01-11 | Sod Conseils Rech Applic | Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof |
WO2002024680A1 (en) * | 2000-09-21 | 2002-03-28 | Smithkline Beecham P.L.C. | Imidazole derivatives as raf kinase inhibitors |
SI1349839T1 (es) * | 2000-12-04 | 2005-08-31 | Hoffmann La Roche | |
CA2454059A1 (en) * | 2001-07-19 | 2003-01-30 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
-
2003
- 2003-08-08 EP EP03749015A patent/EP1536790A2/en not_active Withdrawn
- 2003-08-08 WO PCT/US2003/024912 patent/WO2004014370A2/en active Application Filing
- 2003-08-08 CN CNA038238594A patent/CN1691944A/zh active Pending
- 2003-08-08 CA CA002495120A patent/CA2495120A1/en not_active Abandoned
- 2003-08-08 TW TW092121861A patent/TW200424183A/zh unknown
- 2003-08-08 MX MXPA05001592A patent/MXPA05001592A/es unknown
- 2003-08-08 TW TW096135411A patent/TW200812986A/zh unknown
- 2003-08-08 NZ NZ538339A patent/NZ538339A/en unknown
- 2003-08-08 KR KR1020057002200A patent/KR20050039846A/ko not_active Application Discontinuation
- 2003-08-08 JP JP2004527912A patent/JP2006506340A/ja active Pending
- 2003-08-08 AR ARP030102892A patent/AR041508A1/es unknown
- 2003-08-08 BR BR0313266-8A patent/BR0313266A/pt not_active IP Right Cessation
- 2003-08-08 AU AU2003268064A patent/AU2003268064A1/en not_active Abandoned
- 2003-08-08 US US10/636,965 patent/US20040132726A1/en not_active Abandoned
-
2005
- 2005-02-02 IL IL16665005A patent/IL166650A0/xx unknown
- 2005-02-07 ZA ZA200501101A patent/ZA200501101B/xx unknown
- 2005-03-09 NO NO20051223A patent/NO20051223L/no not_active Application Discontinuation
- 2005-11-10 US US11/270,617 patent/US20060063772A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1536790A2 (en) | 2005-06-08 |
MXPA05001592A (es) | 2005-05-05 |
NZ538339A (en) | 2007-01-26 |
WO2004014370A2 (en) | 2004-02-19 |
TW200812986A (en) | 2008-03-16 |
AU2003268064A1 (en) | 2004-02-25 |
CN1691944A (zh) | 2005-11-02 |
CA2495120A1 (en) | 2004-02-19 |
BR0313266A (pt) | 2005-06-21 |
US20060063772A1 (en) | 2006-03-23 |
US20040132726A1 (en) | 2004-07-08 |
KR20050039846A (ko) | 2005-04-29 |
NO20051223L (no) | 2005-05-03 |
WO2004014370A3 (en) | 2004-10-21 |
JP2006506340A (ja) | 2006-02-23 |
IL166650A0 (en) | 2006-01-15 |
TW200424183A (en) | 2004-11-16 |
ZA200501101B (en) | 2006-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR041508A1 (es) | Compuestos con actividad en los receptores de glutamato metabotropicos | |
AR040847A1 (es) | 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos | |
AR047966A1 (es) | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico | |
AR035479A1 (es) | Derivados de eteres biarilicos y sus sales, composiciones farmaceuticas que los comprenden y procedimientos para el tratamiento de trastornos o afecciones | |
AR038045A1 (es) | Agentes terapeuticos | |
ES2194844T3 (es) | Antagonistas del receptor de aminoacidos excitadores. | |
HN1998000034A (es) | Quinoxalinadionas | |
AR038971A1 (es) | Derivados de bencimidazol n3 alquilado como inhibidores de mek | |
DK0447285T3 (da) | Nephtalenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem | |
AR060318A1 (es) | Isoindolonas potenciadoras de receptores metabotropicos de glutamato, composiciones farmaceuticas que las comprenden y el uso de las mismas en la fabricacion de un medicamento para el tratamiento de trastornos neurologicos y psiquiatricos. | |
AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
AR040700A1 (es) | Derivados de pirimidilsulfonamida como moduladores de receptores de quimioquinas | |
CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
RU94030812A (ru) | Производные фосфоноянтарной кислоты, способ их получения и содержащие эти соединения фармацевтические композиции | |
AR043014A1 (es) | Amino-1,3,5-triazinas n-sustituidas con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas, y su uso como herbicidas y reguladores del crecimiento de las plantas | |
AR056541A1 (es) | Derivados de fenil -1,2,4-oxidiazolona con grupo fenilo ,procedimiento para su preparacion y su uso como productos farmaceuticos | |
AR056893A1 (es) | Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides | |
AR041941A1 (es) | Derivado de 1-aminociclohexano sustituidos en la posicion 4 utilizado como receptor orl1 | |
AR070187A1 (es) | Derivados de dulfonamidas sustituidas | |
MX9202190A (es) | 2-carboxiindoles substituidos que tienen actividad farmaceutica. | |
AR015523A1 (es) | Derivados de 2-ariletil-(piperidin-4-ilmetil)amina, un procedimiento para su preparacion, un medicamento que lo contiene y el empleo de dicho compuestopara la elaboracion de un medicamento para el tratamiento de enfermedades relacionadas con el receptor muscarinico | |
DE69018678T2 (de) | Trizyklische Lactamderivate und pharmazeutische Zusammensetzungen, die sie enthalten. | |
AR045793A1 (es) | Compuestos derivados de 3-heterociclil-indol | |
AR039111A1 (es) | Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |